CUE · Cue Biopharma, Inc.

At the April 13, 2026 annual meeting, Cue Biopharma stockholders elected a refreshed Board with Pasha Sarraf and Pamela Garzone receiving the highest support at over 31 million and 32 million votes respectively, indicating strong investor backing for these nominees amid prior leadership transition. Peter A. Kiener, Frank Morich, Patrick Verheyen, and Jill Broadfoot were also elected, though with higher broker non-votes ranging from 3.4 million to 13.7 million, reflecting varying levels of institutional engagement. The ratification of RSM US LLP as auditors passed overwhelmingly with nearly 59 million for votes and minimal opposition, ensuring continuity in financial oversight for the fiscal year ending December 31, 2026. The advisory vote on executive compensation garnered solid approval with 31.4 million for versus 4.2 million against, signaling alignment on pay practices despite Usman Azam's recent resignation as President, CEO, and director effective March 26, 2026. Most significantly for investors, the approval of the reverse stock split amendment—with 51 million for votes—grants the Board flexibility to implement a 1-for-30 to 1-for-50 consolidation at its discretion, potentially to meet exchange requirements or enhance share price attractiveness without needing further stockholder input. This combination of governance continuity, compensation endorsement, and structural flexibility positions the company for strategic execution post-leadership change.